- Home
- YDES vs PEB Comparison
YDES vs PEB Comparison
Compare YDES & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YDES
- PEB
- Stock Information
- Founded
- YDES 2013
- PEB 2009
- Country
- YDES Taiwan
- PEB United States
- Employees
- YDES N/A
- PEB N/A
- Industry
- YDES
- PEB Real Estate Investment Trusts
- Sector
- YDES
- PEB Real Estate
- Exchange
- YDES Nasdaq
- PEB Nasdaq
- Market Cap
- YDES 1.1B
- PEB 1.2B
- IPO Year
- YDES N/A
- PEB 2009
- Fundamental
- Price
- YDES $12.51
- PEB $10.81
- Analyst Decision
- YDES
- PEB Hold
- Analyst Count
- YDES 0
- PEB 8
- Target Price
- YDES N/A
- PEB $12.29
- AVG Volume (30 Days)
- YDES 46.8K
- PEB 1.8M
- Earning Date
- YDES 09-30-2025
- PEB 11-05-2025
- Dividend Yield
- YDES N/A
- PEB 0.37%
- EPS Growth
- YDES N/A
- PEB N/A
- EPS
- YDES N/A
- PEB N/A
- Revenue
- YDES $510,360.00
- PEB $1,469,933,000.00
- Revenue This Year
- YDES N/A
- PEB $2.11
- Revenue Next Year
- YDES N/A
- PEB $2.83
- P/E Ratio
- YDES N/A
- PEB N/A
- Revenue Growth
- YDES 45.76
- PEB 2.00
- 52 Week Low
- YDES $5.30
- PEB $7.42
- 52 Week High
- YDES $25.00
- PEB $15.12
- Technical
- Relative Strength Index (RSI)
- YDES N/A
- PEB 47.30
- Support Level
- YDES N/A
- PEB $10.56
- Resistance Level
- YDES N/A
- PEB $11.26
- Average True Range (ATR)
- YDES 0.00
- PEB 0.36
- MACD
- YDES 0.00
- PEB 0.02
- Stochastic Oscillator
- YDES 0.00
- PEB 60.08
About YDES YD Bio Limited Ordinary Shares
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.